Clinical Trials Directory

We are doing this study to find out if an experimental drug called AMG 355 (the study drug) is a safe and effective option for people who have a solid tumor form of cancer that is metastatic (spread to surrounding tissues in the body). We want to know how well the study drug works on its own or in combination with an approved cancer drug called pembrolizumab.

We are doing this study to learn if a new study drug called AMG-509 is safe and effective in men who have metastatic, castrate-resistant prostate cancer. AMG-509 is a type of drug that helps a type of immune cells called T cells find and kill prostate cancer cells. The first part of this study will test different doses of AMG-509 in men to learn what side effects the study drug causes and which doses are safe. The second part of the study will see if a safe dose of AMG-509 slows cancer growth. This study will also teach us how long AMG-509 stays in your body, and whether treatment with AMG-509 changes the genes and proteins found in your tumor cells.

We are doing this study to find out if an experimental drug called rocatinlimab (the study drug) is a safe and effective option for people who have moderate or severe asthma. We want to know if it can reduce symptoms and the severity of asthma exacerbations for people who take it.

We are doing this study to find out if an experimental drug called tarlatamab (the study drug) is a safe and effective option for people who have small cell lung cancer (SCLC) that has progressed and spread to other parts of the body.

We are doing this study to find the most effective, safe dose of an experimental drug called xaluritamig (the study drug). We want to know how well this drug works compared to the standard drugs for people who have metastatic castration-resistant prostate cancer.

We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.

We are doing this study to learn more about how androgens, a type of sex hormone, might affect women who have nonalcoholic fatty liver disease (NAFLD). We want to see if they play a role in how the disease effects women over time, and we also want to see what role these hormones might play in the relationship between NAFLD and polycystic ovary syndrome.

We are doing this study to find out if an experimental drug called APL-5125 (the study drug) is a safe and effective for people with select types of gastrointestinal cancer. We are also trying to find the best dose of APL-5125 to use.